English
  • Vibegron

    Vibegron

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Vibegron 1190389-15-1 Dec.01, 2030 PV Completion

     

    [Indication]

    For the treatment of overactive bladder (OAB) with signs of urge urinary incontinence (UUI), urgency, and urinary frequency in adults.

    inquirydetail
  • Vericiguat

    Vericiguat

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Vericiguat 1350653-20-1 37984 May.24, 2031 PV Completion

     

    [Indication]

    For the treatment of adults with symptomatic chronic heart failure with reduced left ventricular ejection fraction to reduce the risk of cardiovascular death and heart failure hospitalization.

    inquirydetail
  • Venetoclax

    Venetoclax

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Venetoclax 1257044-40-8 Jun.27, 2031 PV Completion

     

    [Indication]

    1. For the treatment of patients with CLL with 17p deletion, or with SLL, who have received at least one prior therapy.

    2. In combination with rituximab, for the treatment of patients with previously untreated CLL.

    3. In combination with azacitidine or decitabine or low-dose cytarabine, for the treatment of adults with newly diagnosed AML who are ≥75 years of age or who have comorbidities that preclude the use of intensive induction chemotherapy.

    inquirydetail
  • Velpatasvir

    Velpatasvir

    API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status
    Velpatasvir 1377049-84-7 Nov.16, 2032

     

    [Indication]

    1. For the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection, without cirrhosis or with compensated cirrhosis.

    2. In combination with ribavirin for the treatment of patients with decompensated cirrhosis.

    inquirydetail